# Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

> **NCT05726175** · PHASE2 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Disitamab Vedotin
- **DRUG:** Penpulimab

## Key facts

- **NCT ID:** NCT05726175
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05726175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05726175, "Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05726175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*